White Papers

  1. Don’t Settle For Less. Redefining The Core And Scope Of Study Startup

    This white paper focuses on defining and expanding the definition of study startup, an element of clinical trials that is gaining attention because it offers the greatest opportunity to improve quality while compressing clinical trial timelines.

  2. The Evolution Of Risk Management In Clinical Trials

    The cloud has made anywhere/anytime, centralized monitoring (adaptive-on-site and off-site) of all risk-related trial factors a seamless reality. Looking ahead, the cloud can integrate centralized monitoring, risk management measures, and predictive analytics. It can also create risk repositories, to keep trial costs in check and optimize better quality results for life saving therapies.

  3. Addressing The Data Challenges Of Pharmacovigilance

    As pharmacovigilance adopts next-generation technology by leveraging artificial intelligence (AI) and the cloud, new possibilities are opening up for knowledge generation – and thus value – from the data collected and processed. This paper looks at three important developments around drug safety data and their analysis and how industry is prepared for them.

  4. Patient-Centric Trials: Overcome Enrollment Challenges By Putting Patients First

    Just as patients have a stronger voice in today’s healthcare marketplace, that voice should resonate earlier in the drug development process. By adopting a patient-centric approach during protocol design and in day-to-day study management, sponsors can expect improved patient enrollment and retention, as well as a cleaner study with definitive outcomes.

  5. Industry Perceptions and Expectations: The Role Of ICER As An Independent HTA Organization

    In this paper, ICER’s influence over the payer and manufacturer spheres is evaluated through primary research with these two groups of stakeholders. A secondary budget impact analysis is also conducted in order to estimate the potential savings to the US healthcare system if ICER’s cost effective prices were implemented across a selection of therapeutic areas.

  6. Personalizing Digital Health

    How to develop and deploy novel technologies to reduce patient burden and increase engagement.

  7. Improving Patient Recruitment Rates In Oncology Trials

    The percentage of oncology patients participating in clinical trials is remarkably low: 8.1 percent according to a recent meta-analysis. Read a new report from Syneos Health that shares how enrollment rates and study timelines can be vastly improved by understanding the patient pathway and working to meet patients where they are as they travel along it.  The report shares actionable insights for how to meet patients at the right point in their journey – from understanding the influence of emotional pathways of the patient to selecting and priming sites.

  8. Making The Most Of Clinical Trial Data

    To control costs, improve efficiency, and successfully bring more drugs to market—life-changing, life-saving drugs—pharma and biopharma companies need to follow the lead of the financial industry and forward-thinking health systems. Here, we discuss how a data-driven approach to clinical trials—from patient recruitment to post-regulatory approval—can put an end to missed deadlines, failed studies, and wasted time and money.

  9. The Current Biomarker Landscape In Immuno-Oncology

    Dr. El Mustapha Bahassi, Associate Director of Clinical Laboratories at Medpace gives an overview of Central laboratories and the evolving world of immuno-oncology as well as current immuno-oncology biomarkers and detection methods.

  10. Gene Therapies In Rare Disease: From R&D To Regulatory Approval

    Advancements in science and technology have helped researchers develop new treatments for some of the most common diseases known to man. For rare diseases, however, patients have limited treatment options. Advocacy groups and regulatory authorities continue to encourage rare disease research, and more and more scientists are stepping up to the task.